ABT’s branded-generics segment used to be the largest of the four, but a portion of this business was recently sold to MYL in return for a 22% equity stake (#msg-110385639). During the next few years, new acquisitions in emerging markets will likely increase ABT’s branded-generics segment back to 20-25% of total corporate sales.
All told, ABT derives ~70% of sales from outside the US, one of the highest proportions of any S&P 500 company.
Source: today’s Cowen webcast.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.